Nuclear Medicine Unit, Department of Medicine (DIMED), University of Padua, Via Giustiniani, 35128, Padua, Italy.
Department of Nuclear Medicine, Santa Maria Goretti Hospital, Via Canova 3, 04100, Latina, Italy.
Ann Nucl Med. 2023 Aug;37(8):442-450. doi: 10.1007/s12149-023-01852-x. Epub 2023 Jun 21.
To provide an overview of the current available data about FAPI PET in breast cancer patients, with a perspective point of view. A literature search for studies about FAPI PET in the last 5 years (from 2017 to January 2023) was carried out on MEDLINE databases, such as PubMed, EMBASE, Web of Science and Google Scholar using the following keywords: "PET" AND "FAPI" AND "Breast Cancer" AND "Fibroblast imaging". The Critical Appraisal Skills Program (CASP) checklist for diagnostic test studies was used for testing the quality of selected papers. 13 articles were selected, including 172 patients affected by breast cancer who underwent FAPI-based PET images. CASP checklist was used in 5/13 papers, demonstrating a general low quality. Different types of FAPI-based tracers were used. No difference in terms of FAPI uptake was reported based on the histopathological characteristics, such as immunohistochemistry and grading of breast cancer. FAPI demonstrated more lesions and yielded much higher tumor-to-background ratios than 2-[18F]FDG. Preliminary experiences with FAPI PET in breast cancer showed some advantages than the current available 2-[18F]FDG, although prospective trials are needed to further evaluate its diagnostic utility in clinical practice.
提供关于 FAPI PET 在乳腺癌患者中的现有数据概述，并从透视的角度进行讨论。在 MEDLINE 数据库（如 PubMed、EMBASE、Web of Science 和 Google Scholar）中，对过去 5 年（2017 年至 2023 年 1 月）关于 FAPI PET 的研究进行了文献检索，使用了以下关键字：“PET”和“FAPI”和“乳腺癌”和“成纤维细胞成像”。使用诊断测试研究的批判性评估技能计划 (CASP) 清单来测试所选论文的质量。选择了 13 篇文章，包括 172 名接受基于 FAPI 的 PET 图像检查的乳腺癌患者。在 5/13 篇论文中使用了 CASP 清单，表明总体质量较低。使用了不同类型的基于 FAPI 的示踪剂。基于乳腺癌的组织病理学特征（如免疫组织化学和分级），未报告 FAPI 摄取的差异。与当前可用的 2-[18F]FDG 相比，FAPI 显示出更多的病变，并产生更高的肿瘤与背景比。在乳腺癌中使用 FAPI PET 的初步经验表明其具有一些优势，尽管需要前瞻性试验来进一步评估其在临床实践中的诊断效用。
